Patent · US Active

Engineered CRISPR-Cas9 nucleases with altered PAM specificity

US11286468B2 · kind B2 · utility

2Cited by
20References
35Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 22, 2018
Grant dateMar 29, 2022
Priority date—
Expiry dateJan 10, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2800/80
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.